ARUP LABORATORIES | aruplab.com

PATIENT REPORT

500 Chipeta Way, Salt Lake City, Utah 84108-1221

phone: 801-583-2787, toll free: 800-522-2787

Jonathan R. Genzen, MD, PhD, Chief Medical Officer

Patient Age/Sex:

Unknown

Specimen Collected: 16-Jun-23 15:53

LGI1 Ab IgG CBA w/Reflex to Received: 16-Jun-23 15:53 Report/Verified: 16-Jun-23 16:04

Titer, CSF

Procedure Result Units Reference Interval

LGI1 Ab IgG CBA-IFA Screen, CSF Detected * t1 i1 [< 1:1]

LGI1 Ab IgG Titer by CBA-IFA, CSF Received: 16-Jun-23 15:53 Report/Verified: 16-Jun-23 16:04

Procedure Result Units Reference Interval

LGI1 Ab IgG CBA-IFA Titer, CSF 1:160 * i2 [< 1:1]

Interpretive Text

t1: 16-Jun-23 15:53 (LGI1 Ab IgG CBA-IFA Screen, CSF)
LGI1 Antibody, IgG is detected. Titer results to follow.

Test Information

il: LGI1 Ab IgG CBA-IFA Screen, CSF

INTERPRETIVE INFORMATION: LGI1 Ab IgG CBA-IFA Screen, CSF

Leucine-rich, glioma-inactivated 1 protein (LGI1) IgG antibody may occur as part of the voltage-gated potassium channel (VGKC) complex antibodies.

The presence of LGI1 IgG antibody is mainly associated with limbic encephalitis, hyponatremia, and myoclonic movements. LGI1 IgG antibody is rarely associated with tumors but may occur infrequently in Morvan syndrome, neuromyotonia, and idiopathic epilepsy. The full-spectrum of clinical disorders associated with the LGI1 IgG antibody continues to be defined. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings.

This indirect fluorescent antibody assay utilizes LGI1 transfected cell lines for the detection and semi-quantification of the LGI1 IqG antibody.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i2: LGI1 Ab IgG CBA-IFA Titer, CSF

INTERPRETIVE INFORMATION: LGI1 Ab IgG CBA-IFA Titer, CSF

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 23

Report Request ID: 17763800

23-167-900156

Printed:

19-Jun-23 11:54

Page 1 of 1